Viral Genetics Backs off on their (Lyme) Statements and Claims
Mort Zuckerman
Stanle...@fiu.edu, emcsw...@niaid.nih.gov, afa...@niaid.nih.gov,
Spin...@yahoogroups.com, kshe...@calea.org, fit...@gmail.com,
patrick.f...@usdoj.gov, model...@sbcglobal.net,
jdr...@nejm.org, let...@courant.com, Jgerb...@cdc.gov,
michae...@po.state.ct.us, con...@po.state.ct.us, executive-
edi...@nytimes.com, managin...@nytimes.com, news-
ti...@nytimes.com, biz...@nytimes.com, for...@nytimes.com,
nati...@nytimes.com, dv...@cdc.gov, brigidc...@optonline.net,
tr...@hotmail.com, illino...@aol.com, jle...@courant.com,
tinaj...@yahoo.com, jhorn...@fff.org, thomas...@usdoj.gov,
thoma...@po.state.ct.us, kur...@washpost.com,
georg...@washpost.com, p...@allegorypress.com,
commissi...@po.state.ct.us, brans...@comcast.net,
vts...@comcast.net, o...@po.state.ct.us, freet...@charter.net,
scott....@po.state.ct.us, govern...@po.state.ct.us,
attorney...@po.state.ct.us, randall...@usdoj.gov,
Robert....@yale.edu, edi...@greenwich-post.com,
harol...@yale.edu, sedm...@nswbc.org
Cc: fra...@ucia.gov, dr-ahma...@president.ir,
eugener...@washpost.com, afa...@niaid.nih.gov,
bmi...@newstimes.com, tr...@hotmail.com, rast...@aol.com,
billc...@gmail.com, amcg...@rms-law.com, rjmu...@aol.com,
paulcrai...@yahoo.com, sidney_b...@yahoo.com,
criminal...@usdoj.gov, karla.d...@usdoj.gov,
christophe...@usdoj.gov, richar...@yale.edu,
harol...@yale.edu, james.p...@yale.edu, inq...@aldf.com,
ly...@idsociety.org, meganm...@theatlantic.com,
bob.d...@latimes.com
Subject: Viral Genetics Backs off on their (Lyme) Statements and
Claims
Date: May 21, 2009 8:20 AM
Yeah.
Start by talking to Paul Duray because
Lyme is not an inflammatory disease, but
the New Great Imitators of Pam3Cys
immunosuppression.
This is what happens when you invite
the LDA-tards of Pat Smith, Inc:
http://www.lymediseaseassociation.org
and the stalker and intellectual property
thief, Pam Weintraub, into the realm of
real science.
You're (not) welcome.
Kathleen M. Dickson
http://www.actionlyme.org/PAM3CYS_IMMUNE_SUPPRESSION.htm
============================
http://www.tradingmarkets.com/.site/news/Stock%20News/2338816/
CORRECTION: Viral Genetics Pursues Promising New Therapy for Lyme
Disease With Grant from Time for Lyme, Inc.
Wed. May 20, 2009; Posted: 08:44 PM
Stocks RSS
You too can increase your ETF trading!
SAN MARINO, Calif., May 20, 2009 /PRNewswire-FirstCall via COMTEX/ --
VRAL | Quote | Chart | News | PowerRating -- On April 16, 2009 and
March 18, 2009, biotechnology firm Viral Genetics, Inc. (Pink Sheets:
VRAL | Quote | Chart | News | PowerRating) announced "that the company
is pursing a promising new therapy for Lyme Disease with funding from
Time for Lyme, Inc., and the Turn Corner Foundation." This correction
is to clarify that those grants were not made to Viral Genetics but
were made directly to the University of Colorado where Dr. M. Karen
Newell is a tenured professor. The University then applied the funds
to promising research into a treatment for Lyme Disease that is being
conducted by Dr. M. Karen Newell and her research group at the
University of Colorado. Any inference in the press releases that the
grants were made directly to Viral Genetics rather than the university
is incorrect.
Viral Genetics has certain exclusive licenses and options from the
University of Colorado under previously filed patent rights, the work
by Dr. Karen. Viral Genetics' license with the University is in return
for certain obligations and fees.
Viral Genetics, Inc. is a biotechnology company that discovers and
develops immune-based therapies for HIV, AIDS and other autoimmune
diseases using its thymus nuclear protein compound (TNP). The company
recently entered into an exclusive license agreement with the
University of Colorado and V-Clip Pharmaceuticals (a subsidiary of the
company) to license technology that appears to explain TNP and provide
a means to optimize therapies based on TNP for future clinical trials.
For more information, visit www.viralgenetics.com.
This news release contains forward-looking statements that involve
risks and uncertainties associated with financial projections,
budgets, milestone timelines, clinical development, regulatory
approvals, and other risks described by Viral Genetics, Inc. from time
to time in its periodic reports filed with the SEC and after March 25,
2009, filed on the pink sheets web site. VGV-1 is not approved by the
US Food and Drug Administration or by any comparable regulatory
agencies elsewhere in the world. While Viral Genetics believes that
the forward-looking statements and underlying assumptions contained
therein are reasonable, any of the assumptions could be inaccurate,
including, but not limited to, the ability of Viral Genetics to
establish the efficacy of VGV-1 in the treatment of any disease or
health condition, the development of studies and strategies leading to
commercialization of VGV-1 in the United States, the obtaining of
funding required to carry out the development plan, the completion of
studies and tests on time or at all, and the successful outcome of
such studies or tests. Therefore, there can be no assurance that the
forward-looking statements included in this release will prove to be
accurate. In light of the significant uncertainties inherent in the
forward-looking statements included herein, the forward-looking
statements should not be regarded as a representation by Viral
Genetics or any other person that the objectives and plans of Viral
Genetics will be achieved.
Viral Genetics
Haig Keledjian, 626-334-5310
SOURCE Viral Genetics, Inc.
For full details for VRAL click here.
"[Real] scientists are *fiercely* independent. That's the good
news."-- NIH's Top Fool, Anthony Fauci